Sign up to save your podcasts
Or
Share GLP-1 Daily: Ozempic & Wegovy News
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
GLP-1 Daily: Ozempic & Wegovy News
GLP-1 Daily: Ozempic & Wegovy News episodes
- Mylan Tests Novo's Wegovy Patents as States Target Chinese GLP-1 Supply — September 28, 2026
Mylan is asking a Delaware court to clear its proposed generic Wegovy from a new Novo Nordisk patent. Twenty state attorneys general are warning the White House about Chinese GLP-1 ingredient suppliers, and doctors are flagging a rare vision-loss risk still under study.
In this episode- Mylan asks US court to clear Wegovy generic from Novo patent claims | Reuters — Reuters
Mylan asks US court to clear Wegovy generic from Novo patent claims | Reuters
Skip to main contentExclusive news, data and analytics for financial market professionalsLearn more aboutRefinitivSubscribe# Mylan asks US court to clear Wegovy generic from Novo patent claimsBy Blake BrittainSeptember 25, 20267:23 PM UTCUpdated agoText*Small Text*Medium Text*Large…- Step Back — Mylan is asking a court to clear a Wegovy generic from Novo Nordisk’s patent claims—what would a win actually change for patients, and why wouldn’t it automatically mean a generic could appear immediately?Background sources
- Mylan asks US court to clear Wegovy generic from Novo patent claims | Reuters — Blake Brittain
- Mylan Wants Del. Judge To Clear Wegovy Generic Drug - Law360 — Law360
- Novo Nordisk, Inc. v. Mylan Pharm. Inc. (792 F.Supp.3d 536) - vLex United States — Vlex
- Novo, Mylan Jockey Over Trial Timing in Wegovy Patent Dispute — Bloomberglaw
- Mylan seeks declaratory judgment against Novo Nordisk over newly issued Wegovy patent, aiming to preempt a new Delaware lawsuit – ip fray — Ipfray
- Tennessee AG Skrmetti Joins 20-State Warning over Chinese Weight-Loss Drug Suppliers Linked to Fentanyl Precursors - Tennessee Star — Tennessee Star
Tennessee AG Skrmetti Joins 20-State Warning over Chinese Weight-Loss Drug Suppliers Linked to Fentanyl Precursors - Tennessee Star
# Tennessee AG Skrmetti Joins 20-State Warning over Chinese Weight-Loss Drug Suppliers Linked to Fentanyl PrecursorsSeptember 25, 2026 Tom PappertTennessee Attorney General Jonathan Skrmetti announced this week that his office joined 19 other state attorneys…- Doctor warns of 'eye stroke' risk linked to GLP-1 weight loss drugs - Health - News - Daily Express US — Daily Express US
Doctor warns of 'eye stroke' risk linked to GLP-1 weight loss drugs - Health - News - Daily Express US
## Despite the risk, doctors are warning that diabetes and obesity still have proven health risks if gone untreated.By Cheyenne R. Ubiera15:11 ET, Sun, Sep 27, 2026 Updated: 15:11 ET, Sun, Sep 27, 2026Doctors are warning of a rare eye condition linked to GLP-1 drugs (Image: Corbis via…Daily TopFive for GLP-1 Daily. Links above go to the original articles. Follow and rate GLP-1 Daily wherever you listen. Feedback? Email [email protected].
8 min - Mylan asks US court to clear Wegovy generic from Novo patent claims | Reuters — Reuters
- Mounjaro Misuse in Japan, Contraband GLP-1 Pens Flood Brazil — September 25, 2026
Mounjaro's off-label weight-loss use in Japan has drawn 35 suspected adverse-event reports, including pancreatitis and hypoglycemia. In Brazil, GLP-1 pen seizures in the first half of 2026 were 300% above all of 2025, as gray markets outpace regulated access.
In this episode- Reported Adverse Effects of Maunzar in Japan: Hypoglycemia and Pancreatitis After Use for Weight Loss - The Asia Business Daily — The Asia Business Daily
Reported Adverse Effects of Maunzar in Japan: Hypoglycemia and Pancreatitis After Use for Weight Loss - The Asia Business Daily
# Reported Adverse Effects of Maunzar in Japan: Hypoglycemia and Pancreatitis After Use for Weight Lossby Yun SeulgiPublished 23 Sep.2026 16:13(KST)## 35 Cases Reported After Use for Dieting and Cosmetic PurposesIn Japan, there has been a series of cases where…- LatAm Trafficking of Contraband Weight Loss Drugs — InSight Crime
LatAm Trafficking of Contraband Weight Loss Drugs
# Trafficking of Contraband Weight Loss Drugs From Paraguay to Brazil Spikesby Christopher Newton, Marina Cavalari and Abby Pender 23 Sep 2026 23 Sep 2026Weight loss and diabetes medications are now one of the most smuggled contraband products in Brazil. Pharmaceuticals produced in neighboring Paraguay are being stolen and diverted into…- Eli Lilly says Foundayo draws a third of new pill users | Mugglehead — Mugglehead
Eli Lilly says Foundayo draws a third of new pill users | Mugglehead
# Eli Lilly says Foundayo draws one‑third of new GLP‑1 pill patientsRicks gave no period or patient count for the estimate as Lilly broke ground on its US$6.5 billion Houston ingredients plant.Adrian Kessler· Sep 23, 2026, 5:33 PM EDTUnmarked medicine cartons in a pharmacy dispensary. Illustration: Mugglehead, generated…- AM Best highlights GLP-1 insurance cost pressures in podcast discussion — Traders Union
# AM Best highlights GLP-1 insurance cost pressures in podcast discussion
Published: 2026-09-24T14:18:37+00:00Source: tradersunion.com (tradersunion.com)Language: en## StoryAM Best highlights GLP-1 insurance cost pressures in podcast discussionOleksii Zaichenko 1 hour ago# AM Best highlights GLP-1 insurance cost pressures in podcast discussionGLP-1 costs shake insurersRising use…Daily TopFive for GLP-1 Daily. Links above go to the original articles. Follow and rate GLP-1 Daily wherever you listen. Feedback? Email [email protected].
8 min - Reported Adverse Effects of Maunzar in Japan: Hypoglycemia and Pancreatitis After Use for Weight Loss - The Asia Business Daily — The Asia Business Daily
- Semaglutide heart signal meets FDA import and Medicare access shifts — September 24, 2026
Semaglutide researchers say SELECT’s heart benefit isn’t fully explained by weight loss, but the practical GLP-1 fight is still access, from FDA import restrictions and Medicare Bridge uptake to Novo’s pipeline and oral manufacturing plans. Ask your prescriber before changing treatment.
In this episode- Weight loss alone does not explain lower heart disease for those on semaglutide | EurekAlert! — EurekAlert!
Weight loss alone does not explain lower heart disease for those on semaglutide | EurekAlert!
News Release 23-Sep-2026# Weight loss alone does not explain lower heart disease for those on semaglutideimage: Professor Helen Colhoun view more Credit: Helen Colhoun / European Society of Cardiology- The SELECT trial has already shown a 20% lower risk of heart disease for people with…- China's Sinopep Subsidiary Hit with FDA Import Ban, All Peptide API Sales to US Suspended — BigGo
# China's Sinopep Subsidiary Hit with FDA Import Ban, All Peptide API Sales to US Suspended
Published: 2026-09-22T13:35:30+00:00Source: finance.biggo.com (finance.biggo.com)Language: en## Story# China's Sinopep Subsidiary Hit with FDA Import Ban, All Peptide API Sales to US Suspended- Published: 2026-09-22T13:35:30.000Z- Updated: 2026-09-22T13:36:42.000Z- Author: BigGo Editorial Team-…- Novo’s CagriSema beats lower-dose tirzepatide in diabetes, meets obesity endpoint — AllSci
Novo’s CagriSema beats lower-dose tirzepatide in diabetes, meets obesity endpoint
# Novo’s CagriSema beats lower-dose tirzepatide in diabetes, meets obesity endpointEdited by Robert McTiernan· September 22, 2026· 2 min readNovo Nordisk's cagrilintide and semaglutide combination CagriSema delivered superior weight loss versus a lower dose of tirzepatide in type 2 diabetes and met its primary…- 700,000 Seniors Start GLP-1 Weight-Loss Drugs — but US Taxpayers Cover $195 Per Patient | IBTimes UK — IBTimes UK
700,000 Seniors Start GLP-1 Weight-Loss Drugs — but US Taxpayers Cover $195 Per Patient | IBTimes UK
## Zepbound and Foundayo lead the market as Lilly captures 7 out of 10 new Medicare patientsBy Stephanie Cruz Published 24 September 2026, 1:50 AM BSTSeniors get their weight-loss jabs for a $50 (£37) monthly copay under Medicare's Bridge programme, while drugmakers cash in on a…- Novo aims for 10-fold increase in oral GLP-1 manufacturing capacity | Pharma Manufacturing — Pharma Manufacturing
Novo aims for 10-fold increase in oral GLP-1 manufacturing capacity | Pharma Manufacturing
# Novo aims for 10-fold increase in oral GLP-1 manufacturing capacityThe Danish drugmaker plans to scale production capacity to supply oral obesity therapies to 15 million patients globally by the end of the decade.Greg SlabodkinSept. 22, 2026 5 min read6ab29f6e83303d83b9ca0b11 Novonordisk…Daily TopFive for GLP-1 Daily. Links above go to the original articles. Follow and rate GLP-1 Daily wherever you listen. Feedback? Email [email protected].
9 min - Weight loss alone does not explain lower heart disease for those on semaglutide | EurekAlert! — EurekAlert!
About GLP-1 Daily: Ozempic & Wegovy News
From the publisher's feed
GLP-1 Daily: Ozempic & Wegovy News is a weekday briefing on GLP-1 drugs for patients and anyone about to start one. In about eight minutes, anchor Cassidy and cohost Silvara cover what changed…
today across semaglutide and tirzepatide: Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus and the new oral GLP-1 pills. Expect FDA decisions, clinical trial readouts, supply and shortage updates, safety and side-effect news, and the cost and access story: prior authorization, insurance and Medicaid coverage, employer plans and compounding-pharmacy enforcement. Every efficacy figure is cited, company-reported data is flagged as such, and each story comes back to one question: does this change what you should ask your clinician? No celebrity weight-loss content, before-and-after photos or miracle claims. Not affiliated with Novo Nordisk or Eli Lilly.